The Mayne Pharma Group Ltd (ASX: MYX) share price slumped 1.18% lower to a new 52-week low in yesterday’s trade.
Shares in the Aussie pharmaceuticals group have been trending lower in the last 12 months to just $0.42 per share.
But will Mayne Pharma shares continue to drop, or is now the time to pick the stock up for a steal?
Why Mayne Pharma shares have slumped lower
It’s been a rough 12 months for shareholders in the Aussie pharmaceuticals group who have seen their holdings fall 49.40% over that time.
A disappointing FY19 hurt the Mayne Pharma share price and set the stock on its downwards path.
The group reported a 1% decline in revenue to $525.2 million and a 4% drop in reported earnings before interest, tax, depreciation and amortisation to $111.6 million for the financial year.
Mayne Pharma recorded a net loss after tax of $280.8 million with a huge $351.7 million non-cash impairment on intangibles hurting profits.
While investors were hoping for a turnaround in fortunes, FY20 got off to a disappointing start. Mayne Pharma reported a 16% drop in revenue in the first 4 months compared to the previous year.
That sent Mayne Pharma shares falling even lower to close out the year and towards the current $0.42 mark.
Are the group’s shares a bargain buy?
The Aussie pharmaceuticals group is set to report its half-year results for FY20 on 21 February. Given where Mayne Pharma shares are trading right now, I think that’s a date to mark in your diaries.
A turnaround in earnings and a strong research and development pipeline could be key. The 4-month update at the annual general meeting doesn’t bode well for the February results. However, the group’s shares could also be oversold based on overly negative sentiment in recent months.
If the group can show signs of a turnaround in February, I think the current $0.42 valuation could be an absolute bargain buy.
Personally, I’d prefer to get pharmaceuticals exposure from blue chips like CSL Limited (ASX: CSL) with a strong earnings profile.
The post Are Mayne Pharma shares in the bargain bin? appeared first on Motley Fool Australia.
Here are 3 more ASX dividend shares that I'll be watching in February.
When Edward Vesely -- The Motley Fool Australia's resident dividend expert -- has a stock tip, it can pay to listen. With huge winners like Dicker Data (up 126%) and Collins Food (up 79%) under his belt, Edward is building an enviable following amongst investors that are planning for retirement.
In a brand new report, Edward has just revealed what he believes are the 3 best dividend stocks for income-hungry investors to buy now. All 3 stocks are paying growing fully franked dividends giving you the opportunity to combine capital appreciation with attractive dividend yields.
Best of all, Edward’s “Top 3 Dividend Shares To Buy For 2020” report is totally free to all Motley Fool readers.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares to buy now
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2020
- 5 Stocks for Potentially Building Wealth After 50
Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020